Literature DB >> 15068977

Survival after initial diagnosis of Alzheimer disease.

Eric B Larson1, Marie-Florence Shadlen, Li Wang, Wayne C McCormick, James D Bowen, Linda Teri, Walter A Kukull.   

Abstract

BACKGROUND: Alzheimer disease is an increasingly common condition in older people. Knowledge of life expectancy after the diagnosis of Alzheimer disease and of associations of patient characteristics with survival may help planning for future care.
OBJECTIVE: To investigate the course of Alzheimer disease after initial diagnosis and examine associations hypothesized to correlate with survival among community-dwelling patients with Alzheimer disease.
DESIGN: Prospective observational study.
SETTING: An Alzheimer disease patient registry from a base population of 23 000 persons age 60 years and older in the Group Health Cooperative, Seattle, Washington. PATIENTS: 521 newly recognized persons with Alzheimer disease enrolled from 1987 to 1996 in an Alzheimer disease patient registry. MEASUREMENTS: Baseline measurements included patient demographic features, Mini-Mental State Examination score, Blessed Dementia Rating Scale score, duration since reported onset of symptoms, associated symptoms, comorbid conditions, and selected signs. Survival was the outcome of interest.
RESULTS: The median survival from initial diagnosis was 4.2 years for men and 5.7 years for women with Alzheimer disease. Men had poorer survival across all age groups compared with females. Survival was decreased in all age groups compared with the life expectancy of the U.S. population. Predictors of mortality based on proportional hazards models included a baseline Mini-Mental State Examination score of 17 or less, baseline Blessed Dementia Rating Scale score of 5.0 or greater, presence of frontal lobe release signs, presence of extrapyramidal signs, gait disturbance, history of falls, congestive heart failure, ischemic heart disease, and diabetes at baseline. LIMITATIONS: The base population, although typical of the surrounding Seattle community, may not be representative of other, more diverse populations.
CONCLUSIONS: In this sample of community-dwelling elderly persons who received a diagnosis of Alzheimer disease, survival duration was shorter than predicted on the basis of U.S. population data, especially for persons with onset at relatively younger ages. Features significantly associated with reduced survival at diagnosis were increased severity of cognitive impairment, decreased functional level, history of falls, physical examination findings of frontal release signs, and abnormal gait. The variables most strongly associated with survival were measures of disease severity at the time of diagnosis. These results should be useful to patients and families experiencing Alzheimer disease, other caregivers, clinicians, and policymakers when planning for future care needs.

Entities:  

Mesh:

Year:  2004        PMID: 15068977     DOI: 10.7326/0003-4819-140-7-200404060-00008

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  127 in total

Review 1.  The concept of FDG-PET endophenotype in Alzheimer's disease.

Authors:  Emmanuel H During; R S Osorio; F M Elahi; L Mosconi; M J de Leon
Journal:  Neurol Sci       Date:  2011-06-01       Impact factor: 3.307

2.  Are scores on the physical performance test useful in determination of risk of future falls in individuals with dementia?

Authors:  Mary K Farrell; Richard A Rutt; Michelle M Lusardi; Ann K Williams
Journal:  J Geriatr Phys Ther       Date:  2011 Apr-Jun       Impact factor: 3.381

3.  Frailty syndrome and all-cause mortality in demented patients: the Italian Longitudinal Study on Aging.

Authors:  Vincenzo Solfrizzi; Emanuele Scafato; Vincenza Frisardi; Daniele Sancarlo; Davide Seripa; Giancarlo Logroscino; Marzia Baldereschi; Gaetano Crepaldi; Antonio Di Carlo; Lucia Galluzzo; Claudia Gandin; Domenico Inzitari; Stefania Maggi; Alberto Pilotto; Francesco Panza
Journal:  Age (Dordr)       Date:  2011-04-26

Review 4.  Different models of frailty in predementia and dementia syndromes.

Authors:  F Panza; V Solfrizzi; V Frisardi; S Maggi; D Sancarlo; F Adante; G D'Onofrio; D Seripa; A Pilotto
Journal:  J Nutr Health Aging       Date:  2011-08       Impact factor: 4.075

Review 5.  Pathologic correlates of dementia in individuals with Lewy body disease.

Authors:  Joshua A Sonnen; Nadia Postupna; Eric B Larson; Paul K Crane; Shannon E Rose; Kathleen S Montine; James B Leverenz; Thomas J Montine
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

6.  Drugs for Alzheimer's disease: are they effective?

Authors:  David A Casey; Demetra Antimisiaris; James O'Brien
Journal:  P T       Date:  2010-04

Review 7.  Prospects for delaying the rising tide of worldwide, late-life dementias.

Authors:  Eric B Larson
Journal:  Int Psychogeriatr       Date:  2010-07-01       Impact factor: 3.878

8.  Prevalence estimates for latent neurodegenerative disease.

Authors:  Thomas J Montine
Journal:  Toxicol Pathol       Date:  2010-12-21       Impact factor: 1.902

Review 9.  The Potential of Gonadal Hormone Signalling Pathways as Therapeutics for Dementia.

Authors:  X Du; R A Hill
Journal:  J Mol Neurosci       Date:  2016-08-15       Impact factor: 3.444

10.  Effect of a dementia diagnosis on survival of older patients after a diagnosis of breast, colon, or prostate cancer: implications for cancer care.

Authors:  Mukaila A Raji; Yong-Fang Kuo; Jean L Freeman; James S Goodwin
Journal:  Arch Intern Med       Date:  2008-10-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.